211 related articles for article (PubMed ID: 12538452)
1. Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas.
Le QT; Sutphin PD; Raychaudhuri S; Yu SC; Terris DJ; Lin HS; Lum B; Pinto HA; Koong AC; Giaccia AJ
Clin Cancer Res; 2003 Jan; 9(1):59-67. PubMed ID: 12538452
[TBL] [Abstract][Full Text] [Related]
2. Plasma osteopontin is an independent prognostic marker for head and neck cancers.
Petrik D; Lavori PW; Cao H; Zhu Y; Wong P; Christofferson E; Kaplan MJ; Pinto HA; Sutphin P; Koong AC; Giaccia AJ; Le QT
J Clin Oncol; 2006 Nov; 24(33):5291-7. PubMed ID: 17114663
[TBL] [Abstract][Full Text] [Related]
3. Plasma osteopontin levels in patients with head and neck cancer undergoing chemoradiotherapy.
Snitcovsky I; Leitão GM; Pasini FS; Brunialti KC; Mangone FR; Maistro S; de Castro G; Villar RC; Federico MH
Arch Otolaryngol Head Neck Surg; 2009 Aug; 135(8):807-11. PubMed ID: 19687403
[TBL] [Abstract][Full Text] [Related]
4. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of osteopontin in esophageal squamous cell carcinoma: comparison with common tumor markers.
Shimada Y; Watanabe G; Kawamura J; Soma T; Okabe M; Ito T; Inoue H; Kondo M; Mori Y; Tanaka E; Imamura M
Oncology; 2005; 68(2-3):285-92. PubMed ID: 16015046
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of plasma osteopontin in patients with locoregionally advanced head and neck squamous cell carcinoma treated on TROG 02.02 phase III trial.
Lim AM; Rischin D; Fisher R; Cao H; Kwok K; Truong D; McArthur GA; Young RJ; Giaccia A; Peters L; Le QT
Clin Cancer Res; 2012 Jan; 18(1):301-7. PubMed ID: 22096023
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia upregulates osteopontin expression in NIH-3T3 cells via a Ras-activated enhancer.
Zhu Y; Denhardt DT; Cao H; Sutphin PD; Koong AC; Giaccia AJ; Le QT
Oncogene; 2005 Sep; 24(43):6555-63. PubMed ID: 16007184
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical detection of osteopontin in advanced head-and-neck cancer: prognostic role and correlation with oxygen electrode measurements, hypoxia-inducible-factor-1alpha-related markers, and hemoglobin levels.
Bache M; Reddemann R; Said HM; Holzhausen HJ; Taubert H; Becker A; Kuhnt T; Hänsgen G; Dunst J; Vordermark D
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1481-7. PubMed ID: 17056190
[TBL] [Abstract][Full Text] [Related]
9. Plasma osteopontin levels in patients with head and neck cancer and cervix cancer are critically dependent on the choice of ELISA system.
Vordermark D; Said HM; Katzer A; Kuhnt T; Hänsgen G; Dunst J; Flentje M; Bache M
BMC Cancer; 2006 Aug; 6():207. PubMed ID: 16911785
[TBL] [Abstract][Full Text] [Related]
10. Commentary re: Q-T Le et al, identification of osteopontin as a prognostic marker for head and neck squamous cell carcinomas. clin cancer res, 9: 31-32, 2003.
Denhardt DT
Clin Cancer Res; 2003 Jan; 9(1):31-2. PubMed ID: 12538448
[No Abstract] [Full Text] [Related]
11. Effect of radiation and ibuprofen on normoxic renal carcinoma cells overexpressing hypoxia-inducible factors by loss of von Hippel-Lindau tumor suppressor gene function.
Palayoor ST; Burgos MA; Shoaibi A; Tofilon PJ; Coleman CN
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4158-64. PubMed ID: 15217953
[TBL] [Abstract][Full Text] [Related]
12. Perioperative changes in osteopontin and TGFβ1 plasma levels and their prognostic impact for radiotherapy in head and neck cancer.
Polat B; Kaiser P; Wohlleben G; Gehrke T; Scherzad A; Scheich M; Malzahn U; Fischer T; Vordermark D; Flentje M
BMC Cancer; 2017 Jan; 17(1):6. PubMed ID: 28049456
[TBL] [Abstract][Full Text] [Related]
13. Expression and prognostic significance of a panel of tissue hypoxia markers in head-and-neck squamous cell carcinomas.
Le QT; Kong C; Lavori PW; O'byrne K; Erler JT; Huang X; Chen Y; Cao H; Tibshirani R; Denko N; Giaccia AJ; Koong AC
Int J Radiat Oncol Biol Phys; 2007 Sep; 69(1):167-75. PubMed ID: 17707270
[TBL] [Abstract][Full Text] [Related]
14. Identification of novel VHL target genes and relationship to hypoxic response pathways.
Maina EN; Morris MR; Zatyka M; Raval RR; Banks RE; Richards FM; Johnson CM; Maher ER
Oncogene; 2005 Jun; 24(28):4549-58. PubMed ID: 15824735
[TBL] [Abstract][Full Text] [Related]
15. Influence of hypoxia and irradiation on osteopontin expression in head and neck cancer and glioblastoma cell lines.
Wohlleben G; Scherzad A; Güttler A; Vordermark D; Kuger S; Flentje M; Polat B
Radiat Oncol; 2015 Aug; 10():167. PubMed ID: 26259597
[TBL] [Abstract][Full Text] [Related]
16. An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers.
Le QT; Chen E; Salim A; Cao H; Kong CS; Whyte R; Donington J; Cannon W; Wakelee H; Tibshirani R; Mitchell JD; Richardson D; O'Byrne KJ; Koong AC; Giaccia AJ
Clin Cancer Res; 2006 Mar; 12(5):1507-14. PubMed ID: 16533775
[TBL] [Abstract][Full Text] [Related]
17. Response of the plasma hypoxia marker osteopontin to in vitro hypoxia in human tumor cells.
Said HM; Katzer A; Flentje M; Vordermark D
Radiother Oncol; 2005 Aug; 76(2):200-5. PubMed ID: 16024111
[TBL] [Abstract][Full Text] [Related]
18. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma.
Pan HW; Ou YH; Peng SY; Liu SH; Lai PL; Lee PH; Sheu JC; Chen CL; Hsu HC
Cancer; 2003 Jul; 98(1):119-27. PubMed ID: 12833464
[TBL] [Abstract][Full Text] [Related]
20. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial.
Overgaard J; Eriksen JG; Nordsmark M; Alsner J; Horsman MR;
Lancet Oncol; 2005 Oct; 6(10):757-64. PubMed ID: 16198981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
